These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7823053)

  • 1. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis.
    Ray-Chaudhuri K; Smith C; Gough AC; Novak N; Chamoun V; Wolf CR; Leigh PN
    J Neurol Neurosurg Psychiatry; 1995 Jan; 58(1):109. PubMed ID: 7823053
    [No Abstract]   [Full Text] [Related]  

  • 2. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
    Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
    Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
    [No Abstract]   [Full Text] [Related]  

  • 4. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
    Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
    Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
    Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 8. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics: Part II.
    Gibaldi M
    Ann Pharmacother; 1992 Feb; 26(2):255-61. PubMed ID: 1554942
    [No Abstract]   [Full Text] [Related]  

  • 10. Phenylalanine hydroxylase: A biomarker of disease susceptibility in Parkinson's disease and Amyotrophic lateral sclerosis.
    Steventon GB; Mitchell SC
    Med Hypotheses; 2018 Sep; 118():29-33. PubMed ID: 30037610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine oxidation in Parkinson's disease.
    Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylase polymorphism in Leber's hereditary optic neuropathy.
    Chalmers RM; Bandmann O; Harding AE
    J Neurol Neurosurg Psychiatry; 1996 May; 60(5):588. PubMed ID: 8778272
    [No Abstract]   [Full Text] [Related]  

  • 14. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narcotic analgesics and debrisoquine polymorphism.
    Lavrijsen KL; Heykants JJ
    Anesthesiology; 1989 Sep; 71(3):474-5. PubMed ID: 2570539
    [No Abstract]   [Full Text] [Related]  

  • 16. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
    Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
    Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants of human microsomal enzymes.
    Davies DS; Boobis AR
    Biochem Soc Trans; 1983 Aug; 11(4):459-60. PubMed ID: 6617977
    [No Abstract]   [Full Text] [Related]  

  • 19. Debrisoquine hydroxylation in Parkinson's disease.
    Steiger MJ; Lledo P; Quinn NP; Marsden CD; Turner P; Jenner PG
    Acta Neurol Scand; 1992 Aug; 86(2):159-64. PubMed ID: 1414226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
    Distlerath LM; Guengerich FP
    Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.